Medical Condition News

RSS

ART safe and effective for treating combat-related symptoms of PTSD among veterans

Accelerated Resolution Therapy, or ART, is a brief, safe, and effective treatment for combat-related symptoms of post-traumatic stress disorder among veterans and U.S. service members, researchers at University of South Florida College of Nursing report in a new study. They found this newer treatment -- a combination of evidence-based psychotherapies and use of eye movements -- was shorter and more likely to be completed, than conventional therapies formally endorsed by the U.S. Department of Defense and the Veterans Administration.

9 Dec 2013

Equations help explain key parameters of stents that combat artherosclerosis

Coronary heart disease accounts for 18% of deaths in the United States every year. The disease results from a blockage of one or more arteries that supply blood to the heart muscle.

9 Dec 2013

CRAB CTC enrolls first patient into inaugural cancer clinical trial

Cancer Research And Biostatistics today announced enrollment of the first patient into the inaugural clinical trial sponsored by its Clinical Trials Consortium. The CRAB CTC mission is to ensure rapid clinical testing of new and innovative cancer treatments, and is focusing on lung cancer as its first target. By engaging frontline treating oncologists to push the boundaries of patient care, the aim is to improve the standard of care and extend overall survival.

9 Dec 2013

Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation

Bone homeostasis requires precise balance between deposition of new bone by osteoblasts and resorption of old bone by osteoclasts. Bone diseases, including osteoporosis and rheumatoid arthritis, are the result of increased osteoclast activity and formation, which allows bone resorption to outpace deposition.

9 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

Older people with diabetes are susceptible to nonfatal cardiovascular complications, hypoglycemic events

Cardiovascular complications and hypoglycemia (low blood sugar) were common nonfatal complications in adults 60 years of age and older with diabetes, according to a study published by JAMA Internal Medicine, a JAMA Network publication.

9 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

Lung cancer screening using low-dose CT reduces mortality in high-risk smokers

Previous evidence, including published National Lung Cancer Screening Trial (NLST) results, shows that computed tomography (CT) lung cancer screening significantly reduces lung cancer deaths in high risk patients*, and is appropriate, with careful patient selection and follow-up.

9 Dec 2013

MUC5B protein plays key role in many lung-related ailments

An international team of researchers has zeroed in on a protein that plays a key role in many lung-related ailments, from seasonal coughing and hacking to more serious diseases such as MRSA infections and cystic fibrosis.

9 Dec 2013

Research explores epigenetic effects that contribute to psychiatric disorders in offspring

Advanced paternal age has been associated with greater risk for psychiatric disorders, such as schizophrenia and autism. With an increase in paternal age, there is a greater frequency of certain types of mutations that contribute to these disorders in offspring.

9 Dec 2013

Growing cord blood stem cells in lab before transplant boosts survival, study finds

Donated umbilical cord blood contains stem cells that can save the lives of patients with leukemia, lymphoma and other blood cancers.

9 Dec 2013

Genetic deficiency in males can trigger hepatocellular carcinoma, type 2 diabetes

Michigan State University researchers have uncovered a genetic deficiency in males that can trigger the development of one of the most common types of liver cancer and forms of diabetes.

9 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.

9 Dec 2013

Signs of inflammation in man’s prostate biopsy may indicate reduced risk

Signs of inflammation in a man’s prostate biopsy may indicate he has a reduced risk of subsequently being diagnosed with prostate cancer in a future biopsy. That’s the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

9 Dec 2013

Prana completes treatment phase of IMAGINE Alzheimer’s Disease clinical trial

Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer’s Disease clinical trial.

9 Dec 2013

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) compared to Glivec (imatinib) at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Glivec, and patients who failed to respond to frontline Glivec (as defined by 2013 European LeukemiaNet [ELN] guidelines).

9 Dec 2013

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine on the investigational chimeric antigen receptor therapy, CTL019. Several studies being presented at the American Society of Hematology annual meeting add to the scientific understanding of CTL019 in the treatment of acute lymphoblastic leukemia and chronic lymphocytic leukemia and build on earlier research findings.

9 Dec 2013

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children's Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.

9 Dec 2013

Researchers identify central switch by which HDL controls inflammatory response

High-density lipoprotein, known colloquially as "good cholesterol", protects against dangerous deposits in the arteries. An important function of HDL is its anti-inflammatory properties. An international research team at the Institute of Innate Immunity at the University Hospital of Bonn and the LIMES Institute at the University of Bonn has identified a central switch by which HDL controls the inflammatory response. The results are presented in the current issue of "Nature Immunology".

9 Dec 2013

Medical Condition News

ART safe and effective for treating combat-related symptoms of PTSD among veterans

Equations help explain key parameters of stents that combat artherosclerosis

CRAB CTC enrolls first patient into inaugural cancer clinical trial

Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Older people with diabetes are susceptible to nonfatal cardiovascular complications, hypoglycemic events

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Lung cancer screening using low-dose CT reduces mortality in high-risk smokers

MUC5B protein plays key role in many lung-related ailments

Research explores epigenetic effects that contribute to psychiatric disorders in offspring

Growing cord blood stem cells in lab before transplant boosts survival, study finds

Genetic deficiency in males can trigger hepatocellular carcinoma, type 2 diabetes

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Signs of inflammation in man’s prostate biopsy may indicate reduced risk

Prana completes treatment phase of IMAGINE Alzheimer’s Disease clinical trial

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Children and adults with high-risk ALL benefit from novel, personalized cell therapy

Researchers identify central switch by which HDL controls inflammatory response

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News